Insulet Corporation (PODD)
Stock Price:
$241.14 USD
-4.69 (-1.91%)
Updated Oct 21, 2020 4:00 PM EDT - Market closed
After-hours: $240.46 -0.68 (-0.28%) Oct 21, 4:33 PM
Key Info
| Market Cap |
15.83B |
| Revenue (ttm) |
825.81M |
| Net Income (ttm) |
18.12M |
| Shares Out |
65.65M |
| EPS (ttm) |
0.29 |
| PE Ratio |
831.52 |
| Forward PE |
185.19 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 21, 2020 |
| Last Price |
$241.14 |
| Previous Close |
$245.83 |
| Change ($) |
-4.69 |
| Change (%) |
-1.91% |
| Day's Open |
245.60 |
| Day's Range |
237.60 - 248.74 |
| Day's Volume |
246,447 |
| 52-Week Range |
121.00 - 255.39 |
More Stats
| Market Cap |
15.83B |
| Enterprise Value |
15.90B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
65.65M |
| Float |
64.83M |
| EPS (basic) |
0.28 |
| EPS (diluted) |
0.29 |
| FCF / Share |
-0.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.12% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.44M |
| Short Ratio |
5.50 |
| Short % of Float |
3.76% |
| Beta |
0.72 |
| PE Ratio |
831.52 |
| Forward PE |
185.19 |
| P/FCF Ratio |
n/a |
| PS Ratio |
19.17 |
| PB Ratio |
29.21 |
| Revenue |
825.81M |
| Operating Income |
70.13M |
| Net Income |
18.12M |
| Free Cash Flow |
-22.53M |
| Net Cash |
-65.80M |
| Net Cash / Share |
-1.00 |
| Gross Margin |
58.16% |
| Operating Margin |
8.49% |
| Profit Margin |
2.20% |
| FCF Margin |
-2.73% |
| ROA |
3.36% |
| ROE |
4.45% |
| ROIC |
4.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (21)
| Buy |
7 |
| Overweight |
2 |
| Hold |
11 |
| Underweight |
1 |
| Sell |
0 |
Analyst Consensus: Overweight
Price Target
$244.35*
(1.33% upside)
Low
210
Current: $241.14
High
285
Target: 244.35
*Average 12-month price target from 17 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 738 | 564 | 464 | 367 | 264 | 231 | 247 | 211 | 152 | 96.97 |
| Revenue Growth | 30.93% | 21.56% | 26.38% | 39.07% | 14.08% | -6.38% | 16.9% | 38.83% | 57.02% | - |
| Gross Profit | 480 | 370 | 277 | 211 | 133 | 127 | 112 | 92.34 | 66.71 | 43.73 |
| Operating Income | 50.00 | 27.40 | -7.40 | -10.70 | -48.74 | -8.87 | -29.14 | -35.97 | -42.47 | -38.63 |
| Net Income | 11.60 | 3.30 | -26.80 | -28.88 | -73.52 | -51.50 | -44.97 | -51.87 | -45.83 | -61.16 |
| Shares Outstanding | 60.59 | 58.86 | 58.00 | 57.25 | 56.79 | 55.63 | 54.01 | 47.92 | 46.69 | 39.61 |
| Earnings Per Share | 0.19 | 0.05 | -0.46 | -0.51 | -1.29 | -0.92 | -0.83 | -1.08 | -0.98 | -1.54 |
| EPS Growth | 280% | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow | 98.40 | 35.90 | 41.30 | 15.91 | -12.55 | 8.92 | 3.35 | -29.06 | -25.45 | -35.63 |
| Capital Expenditures | -164 | -157 | -73.80 | -22.12 | -10.61 | -11.49 | -7.31 | -10.99 | -11.11 | -6.55 |
| Free Cash Flow | -65.30 | -122 | -32.50 | -6.20 | -23.16 | -2.57 | -3.96 | -40.05 | -36.57 | -42.17 |
| Cash & Equivalents | 376 | 289 | 440 | 299 | 123 | 151 | 150 | 57.29 | 93.96 | 113 |
| Total Debt | 888 | 592 | 566 | 333 | 177 | 170 | 122 | 118 | 109 | 69.43 |
| Net Cash / Debt | -512 | -303 | -126 | -34.20 | -54.81 | -18.47 | 28.05 | -60.87 | -14.59 | 43.84 |
| Assets | 1,143 | 929 | 817 | 457 | 275 | 297 | 288 | 198 | 221 | 156 |
| Liabilities | 1,067 | 717 | 658 | 393 | 241 | 213 | 163 | 154 | 139 | 90.00 |
| Book Value | 75.90 | 212 | 159 | 63.15 | 34.05 | 83.83 | 125 | 44.18 | 82.74 | 66.23 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Insulet Corporation |
| Country |
United States |
| Employees |
1,350 |
| CEO |
Shacey Petrovic |
Stock Information
| Ticker Symbol |
PODD |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: PODD |
| IPO Date |
May 15, 2007 |
Description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. Its Omnipod System comprise two devices: a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, and its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, and the Middle East. Insulet Corporation was founded in 2000 and is headquartered in Acton, Massachusetts.